<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084707</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1066-A6431117</org_study_id>
    <secondary_id>2008-006279-65</secondary_id>
    <nct_id>NCT01084707</nct_id>
  </id_info>
  <brief_title>Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.</brief_title>
  <official_title>Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of three products for oral nicotine replacement with respect to pharmacokinetics
      after multiple-doses of nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares a new oral Nicotine Replacement Therapy (NRT) product with NiQuitin™
      lozenge 4 mg and Nicorette®gum 4 mg, after 12 hours of nicotine abstinence, with respect to
      steady-state nicotine pharmacokinetics, during 12 hours after start of the first
      administration. Multiple doses of each treatment are given once hourly during five separate
      treatment visits scheduled in a crossover setting with randomized treatment sequences. The
      study will include 40 healthy smokers between 18-50 years, who have been smoking at least 20
      cigarettes daily during at least one year preceding inclusion. Subjects and study personnel
      will be aware of which treatment is administered at a given visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
    <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Concentration</measure>
    <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
    <description>Pharmacokinetic measurement - average concentration during the last dosing interval (AUCtau)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration</measure>
    <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
    <description>The time at which maximum concentration is reached (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration</measure>
    <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
    <description>The minimum nicotine plasma concentration during the last dosing interval (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-Trough Fluctuation</measure>
    <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
    <description>Percent of peak-trough fluctuation over one dosing interval at steady state (PTF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine Plasma Concentration</measure>
    <time_frame>One hour after start of treatment</time_frame>
    <description>The nicotine concentration in plasma (area under the nicotine plasma concentration curve) 1 hour after start of treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Oral Nicotine 24-SA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Self-administrations of Experimental Nicotine once every hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nicotine 24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 administrations of Experimental Nicotine by study personnel once every hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Nicotine 48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 administrations of Experimental Nicotine by study personnel once every 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NiQuitin™ Lozenge 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 NiQuitin™ lozenge, administered by study personnel once every hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette® Gum 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 piece Nicorette® gum, chewed for 30 minutes once every hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Nicotine</intervention_name>
    <description>Oral Nicotine either self-administered or provided by study personnel within 12 hours</description>
    <arm_group_label>Oral Nicotine 24-SA</arm_group_label>
    <arm_group_label>Oral Nicotine 24</arm_group_label>
    <arm_group_label>Oral Nicotine 48</arm_group_label>
    <other_name>generic Nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Lozenge</intervention_name>
    <description>Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours</description>
    <arm_group_label>NiQuitin™ Lozenge 4 mg</arm_group_label>
    <other_name>NiQuitin™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <description>Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours</description>
    <arm_group_label>Nicorette® Gum 4 mg</arm_group_label>
    <other_name>Nicorette®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy smokers, smoking at least 20 cigarettes daily during at least one year
             preceding inclusion and BMI between 17.5 and 30.0 kg/m2.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 month
             preceding the first dose of study medication.

          -  Prior regular use of nicotine mouth spray
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology</name>
      <address>
        <city>Lund</city>
        <zip>222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>April 16, 2010</results_first_submitted>
  <results_first_submitted_qc>October 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2010</results_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation, Nicotine pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a five-arm cross-over trial, with subjects randomized to the order they received the different treatments and with analysis performed on valid pharmacokinetic data. Therefore, Number of Participants Analyzed in each arm represents the same subjects, and the total is not consistent with numbers provided in the participant flow module.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All subjects randomized into the trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Subjects</title>
          <description>All subjects randomized into the trial, e.g., Full Analysis Set</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration</title>
        <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
        <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 48</title>
            <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
          </group>
          <group group_id="O4">
            <title>NiQuitin™ Lozenge 4 mg</title>
            <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration</title>
          <description>Cmax, which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered measured in nanograms/milliliter (ng/ml)</description>
          <units>(ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" spread="6.12"/>
                    <measurement group_id="O2" value="16.49" spread="4.99"/>
                    <measurement group_id="O3" value="30.07" spread="9.77"/>
                    <measurement group_id="O4" value="27.07" spread="10.95"/>
                    <measurement group_id="O5" value="25.96" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration</title>
        <description>The time at which maximum concentration is reached (Tmax)</description>
        <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 48</title>
            <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
          </group>
          <group group_id="O4">
            <title>NiQuitin™ Lozenge 4 mg</title>
            <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Concentration</title>
          <description>The time at which maximum concentration is reached (Tmax)</description>
          <population>ITT</population>
          <units>(minutes)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="9.0" lower_limit="5.0" upper_limit="42.0"/>
                    <measurement group_id="O2" value="10.0" spread="9.2" lower_limit="5.0" upper_limit="45.0"/>
                    <measurement group_id="O3" value="10.0" spread="5.3" lower_limit="5.0" upper_limit="23.0"/>
                    <measurement group_id="O4" value="25.0" spread="10.4" lower_limit="13.0" upper_limit="55.0"/>
                    <measurement group_id="O5" value="30.0" spread="9.1" lower_limit="10.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Plasma Concentration</title>
        <description>The minimum nicotine plasma concentration during the last dosing interval (Cmin)</description>
        <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 48</title>
            <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
          </group>
          <group group_id="O4">
            <title>NiQuitin™ Lozenge 4 mg</title>
            <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma Concentration</title>
          <description>The minimum nicotine plasma concentration during the last dosing interval (Cmin)</description>
          <population>ITT</population>
          <units>(ng/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" spread="4.71"/>
                    <measurement group_id="O2" value="11.67" spread="4.04"/>
                    <measurement group_id="O3" value="25.32" spread="8.41"/>
                    <measurement group_id="O4" value="22.14" spread="9.71"/>
                    <measurement group_id="O5" value="19.00" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak-Trough Fluctuation</title>
        <description>Percent of peak-trough fluctuation over one dosing interval at steady state (PTF)</description>
        <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 48</title>
            <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
          </group>
          <group group_id="O4">
            <title>NiQuitin™ Lozenge 4 mg</title>
            <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Peak-Trough Fluctuation</title>
          <description>Percent of peak-trough fluctuation over one dosing interval at steady state (PTF)</description>
          <population>ITT</population>
          <units>Percent Fluctuation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="14.2"/>
                    <measurement group_id="O2" value="38.4" spread="14.9"/>
                    <measurement group_id="O3" value="21.7" spread="8.7"/>
                    <measurement group_id="O4" value="29.1" spread="10.7"/>
                    <measurement group_id="O5" value="36.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nicotine Plasma Concentration</title>
        <description>The nicotine concentration in plasma (area under the nicotine plasma concentration curve) 1 hour after start of treatment</description>
        <time_frame>One hour after start of treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Nicotine Plasma Concentration</title>
          <description>The nicotine concentration in plasma (area under the nicotine plasma concentration curve) 1 hour after start of treatment</description>
          <population>ITT</population>
          <units>(ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="1.60"/>
                    <measurement group_id="O2" value="4.76" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Concentration</title>
        <description>Pharmacokinetic measurement - average concentration during the last dosing interval (AUCtau)</description>
        <time_frame>During the last dosing interval (hour 11-12 post-dose)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Nicotine 24-SA</title>
            <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O2">
            <title>Oral Nicotine 24</title>
            <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
          </group>
          <group group_id="O3">
            <title>Oral Nicotine 48</title>
            <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
          </group>
          <group group_id="O4">
            <title>NiQuitin™ Lozenge 4 mg</title>
            <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
          </group>
          <group group_id="O5">
            <title>Nicorette® Gum 4 mg</title>
            <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration</title>
          <description>Pharmacokinetic measurement - average concentration during the last dosing interval (AUCtau)</description>
          <population>ITT</population>
          <units>(ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" spread="5.55"/>
                    <measurement group_id="O2" value="14.04" spread="4.50"/>
                    <measurement group_id="O3" value="27.50" spread="9.18"/>
                    <measurement group_id="O4" value="23.70" spread="9.86"/>
                    <measurement group_id="O5" value="22.15" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Nicotine 24-SA</title>
          <description>Oral Nicotine 24 mg, 2 1mg self-administrations once every hour; 12 doses of 2 mg over 11 hours</description>
        </group>
        <group group_id="E2">
          <title>Oral Nicotine 24</title>
          <description>Oral Nicotine 24 mg, 2 1mg administrations by study personnel once every hour; 12 doses of 2 mg over 11 hours</description>
        </group>
        <group group_id="E3">
          <title>Oral Nicotine 48</title>
          <description>Oral Nicotine 48 mg, 2 1mg administrations by study personnel once every 30 minutes; 24 doses of 2 mg over 11.5 hours</description>
        </group>
        <group group_id="E4">
          <title>NiQuitin™ Lozenge 4 mg</title>
          <description>NiQuitin™ lozenge 4 mg; 12 doses of NiQuitin™ lozenge 4 mg over 11 hours</description>
        </group>
        <group group_id="E5">
          <title>Nicorette® Gum 4 mg</title>
          <description>12 doses of NICORETTE® gum 4 mg over 11 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lacrimation Increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrheoa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngial Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <description>Total number of subjects affected in the safety analysis set in arms where the data lies above the 5% threshold</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce Hauze, Sr. Specialist, Clinical Research Operations</name_or_title>
      <organization>J&amp;J Consumer and Personal Products Worldwide</organization>
      <phone>928-277-0715</phone>
      <email>jhauze@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

